← Back to overview

LLY Eli Lilly and Company

Pharmaceuticals · $1,196.03 +0.86%
Price Alert:
Price & Volume
RSI (14)
MACD (12, 26, 9)

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
54.8
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
1,197.33 / 1,191.02 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
0.71 / 1.65
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
42.5
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
1.07T
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
0.58%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
623.78 – 1,249.45
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Eli Lilly and Company is trading at $1,196.03, +0.86% versus the previous close. The price is near its 52-week high — the top of its recent trading range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Johnson & Johnson Is Becoming A Narrower Company Than You Bought
Trefis · 2026-07-25 14:30
Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts
Investor's Business Daily · 2026-07-25 12:00
Jim Cramer Wants Novo Nordisk A/S (NYSE:NVO) To Compete With Eli Lilly In The Market & Not The Courts
Insider Monkey · 2026-07-25 07:48
Nasdaq lags on angst over AI spending ahead of earnings reports
Reuters Videos · 2026-07-24 22:19
Sector Update: Healthcare Stocks Higher Late Afternoon
MT Newswires · 2026-07-24 19:35
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
GuruFocus.com · 2026-07-24 18:45
Eli Lilly and Novo Nordisk Are Locked in a Legal War. Don’t Lose Sight of the Main Event.
Barrons.com · 2026-07-24 18:32
This Catalyst Makes Eli Lilly a Top Growth Stock in 2026
24/7 Wall St. · 2026-07-24 17:30
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.